JP2012508163A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012508163A5 JP2012508163A5 JP2011533632A JP2011533632A JP2012508163A5 JP 2012508163 A5 JP2012508163 A5 JP 2012508163A5 JP 2011533632 A JP2011533632 A JP 2011533632A JP 2011533632 A JP2011533632 A JP 2011533632A JP 2012508163 A5 JP2012508163 A5 JP 2012508163A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody construct
- acute lymphoblastic
- lymphoblastic leukemia
- single chain
- construct according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 17
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 14
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 13
- 208000007660 Residual Neoplasm Diseases 0.000 claims 9
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 claims 7
- 230000008707 rearrangement Effects 0.000 claims 4
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 claims 3
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 2
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 208000023138 childhood B-cell acute lymphoblastic leukemia Diseases 0.000 claims 2
- 238000001514 detection method Methods 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 239000002243 precursor Substances 0.000 claims 2
- 230000000306 recurrent effect Effects 0.000 claims 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 claims 1
- 208000008691 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 108700019889 TEL-AML1 fusion Proteins 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 230000000719 anti-leukaemic effect Effects 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 238000011476 stem cell transplantation Methods 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11232308P | 2008-11-07 | 2008-11-07 | |
| US61/112,323 | 2008-11-07 | ||
| US18329109P | 2009-06-02 | 2009-06-02 | |
| US61/183,291 | 2009-06-02 | ||
| US22126909P | 2009-06-29 | 2009-06-29 | |
| US61/221,269 | 2009-06-29 | ||
| PCT/EP2009/007969 WO2010052013A1 (en) | 2008-11-07 | 2009-11-06 | Treatment of pediatric acute lymphoblastic leukemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015163116A Division JP6130451B2 (ja) | 2008-11-07 | 2015-08-20 | 小児急性リンパ芽球性白血病の新規治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012508163A JP2012508163A (ja) | 2012-04-05 |
| JP2012508163A5 true JP2012508163A5 (enExample) | 2013-03-21 |
| JP5798036B2 JP5798036B2 (ja) | 2015-10-21 |
Family
ID=41796119
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533632A Active JP5798036B2 (ja) | 2008-11-07 | 2009-11-06 | 小児急性リンパ芽球性白血病の新規治療 |
| JP2015163116A Active JP6130451B2 (ja) | 2008-11-07 | 2015-08-20 | 小児急性リンパ芽球性白血病の新規治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015163116A Active JP6130451B2 (ja) | 2008-11-07 | 2015-08-20 | 小児急性リンパ芽球性白血病の新規治療 |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20110262440A1 (enExample) |
| EP (4) | EP2344539B1 (enExample) |
| JP (2) | JP5798036B2 (enExample) |
| KR (1) | KR101695329B1 (enExample) |
| CN (2) | CN102209729B (enExample) |
| AU (1) | AU2009313039B2 (enExample) |
| BR (1) | BRPI0921341A2 (enExample) |
| CA (1) | CA2742242C (enExample) |
| CY (3) | CY1116160T1 (enExample) |
| DK (3) | DK2918604T3 (enExample) |
| ES (3) | ES2748126T3 (enExample) |
| HK (1) | HK1255590B (enExample) |
| HR (3) | HRP20150400T1 (enExample) |
| HU (3) | HUE025452T2 (enExample) |
| IL (1) | IL212651A (enExample) |
| LT (2) | LT2918604T (enExample) |
| MX (1) | MX2011002931A (enExample) |
| NO (1) | NO2918604T3 (enExample) |
| NZ (1) | NZ591312A (enExample) |
| PL (3) | PL2918604T3 (enExample) |
| PT (3) | PT2344539E (enExample) |
| RS (3) | RS53980B1 (enExample) |
| RU (3) | RU2536933C2 (enExample) |
| SG (1) | SG195549A1 (enExample) |
| SI (3) | SI2344539T1 (enExample) |
| SM (3) | SMT201800149T1 (enExample) |
| WO (1) | WO2010052013A1 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| RS53980B1 (sr) * | 2008-11-07 | 2015-10-30 | Amgen Research (Munich) Gmbh | Tretiranje akutne limfoblastne leukemije kod dece |
| ES2565439T3 (es) * | 2009-01-09 | 2016-04-04 | Oxford Biomedica (Uk) Ltd | Factores |
| US20150231241A1 (en) * | 2012-08-14 | 2015-08-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| HK1209434A1 (en) * | 2012-11-13 | 2016-04-01 | Astellas Pharma Inc. | Agents for treatment of claudin expressing cancer diseases |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| CN103131777A (zh) * | 2013-02-05 | 2013-06-05 | 南京艾迪康医学检验所有限公司 | 用于检测e2a-pbx融合基因相对表达量的试剂盒 |
| WO2015121383A1 (en) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| TWI701042B (zh) | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| LT3149480T (lt) | 2014-05-30 | 2019-04-25 | Amgen Research (Munich) Gmbh | B ląstelių pirmtakų ūmia limfoblastine leukemija (all) sergančių pacientų rizikos stratifikacijos būdas |
| EP3175001B1 (en) | 2014-07-30 | 2021-02-10 | Mor Research Applications Ltd. | Prognostic methods and systems of treatment for acute lymphoblastic leukemia |
| WO2016061368A1 (en) * | 2014-10-15 | 2016-04-21 | The Children's Hospital Of Philadelphia | Compositions and methods for treating b-lymphoid malignancies |
| SMT202000438T1 (it) | 2014-11-17 | 2020-09-10 | Regeneron Pharma | Metodi per trattamento di tumore usando l'anticorpo bispecifico cd3xcd20 |
| AU2016215110A1 (en) * | 2015-02-05 | 2017-09-21 | Stc.Unm | Anti-pre-BCR antagonists and methods |
| PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
| PT3280729T (pt) | 2015-04-08 | 2022-08-01 | Novartis Ag | Terapias para cd20, terapias para cd22 e terapias de combinação com uma célula que expressa o recetor de antigénio quimérico (car) para cd19 |
| DK3298042T3 (da) * | 2015-05-20 | 2025-02-24 | Amgen Res Munich Gmbh | B-celledepletering som en diagnostisk markør |
| KR20180087401A (ko) * | 2015-12-22 | 2018-08-01 | 리제너론 파아마슈티컬스, 인크. | 급성 림프아구성 백혈병을 치료하기 위한 이중특이성 항-cd20/항-cd3 항체 |
| GB201602974D0 (en) * | 2016-02-19 | 2016-04-06 | Clube Jasper R | Engineered cells & methods (1) |
| BR112018068628A2 (pt) * | 2016-03-14 | 2019-07-30 | Millennium Pharm Inc | método de prevenção de doença do enxerto contra hospedeiro |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| JP2020511462A (ja) | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物 |
| UY37726A (es) * | 2017-05-05 | 2018-11-30 | Amgen Inc | Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados |
| MX2019014268A (es) | 2017-06-02 | 2020-08-03 | Juno Therapeutics Inc | Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| KR102083481B1 (ko) | 2018-03-22 | 2020-03-02 | 강원대학교산학협력단 | 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물 |
| LT3844189T (lt) | 2018-08-31 | 2025-02-25 | Regeneron Pharmaceuticals, Inc. | Cd3/cd20 bispecifinių antikūnų dozavimo strategija, mažinanti citokinų išsiskyrimo sindromą |
| BR112021014255A2 (pt) * | 2019-01-30 | 2022-01-18 | Wistar Inst | Molécula de ácido nucleico, composição, e, método de prevenção ou tratamento de uma doença ou distúrbio |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| CU20210096A7 (es) | 2019-05-21 | 2022-06-06 | Novartis Ag | Moléculas de unión a cd19 |
| TWI809286B (zh) | 2019-07-05 | 2023-07-21 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| MX2022015872A (es) | 2020-06-11 | 2023-05-16 | Provention Bio Inc | Metodos y composiciones para prevenir diabetes tipo 1. |
| IL305188A (en) | 2021-02-16 | 2023-10-01 | Childrens Health Care D/B/A Childrens Minnesota | Methods for treating B-ALL by administering a pre-BCR complex antagonist |
| WO2023062188A1 (en) | 2021-10-15 | 2023-04-20 | Amgen Research (Munich) Gmbh | Subcutaneous administration of cd19-binding t cell engaging antibodies |
| US20250146017A1 (en) | 2023-11-06 | 2025-05-08 | City Of Hope | Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers |
| WO2025137344A1 (en) | 2023-12-20 | 2025-06-26 | Bristol-Myers Squibb Company | Antibodies targeting il-18 receptor beta (il-18rβ) and related methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008875A1 (de) * | 1996-08-28 | 1998-03-05 | Viva Diagnostika Diagnostische Produkte Gmbh | Kombinationspräparationen und ihre verwendung in der immundiagnostik und immuntherapie |
| JP4169478B2 (ja) * | 1998-04-21 | 2008-10-22 | マイクロメット アーゲー | Ｃｄ１９×ｃｄ３特異的ポリペプチドおよびその使用 |
| WO2004106381A1 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders |
| US8076459B2 (en) * | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| PT1976886E (pt) | 2005-12-16 | 2015-03-09 | Amgen Res Munich Gmbh | Meios e processos para o tratamento de doenças tumorais |
| ES2402591T3 (es) * | 2006-08-14 | 2013-05-07 | Xencor Inc. | Anticuerpos optimizados que seleccionan como diana CD19 |
| ES2582603T5 (es) * | 2008-10-01 | 2022-12-02 | Amgen Res Munich Gmbh | Anticuerpos biespecíficos de cadena sencilla con especificidad por antígenos diana de alto peso molecular |
| RS53980B1 (sr) * | 2008-11-07 | 2015-10-30 | Amgen Research (Munich) Gmbh | Tretiranje akutne limfoblastne leukemije kod dece |
| PL2511264T3 (pl) * | 2009-01-19 | 2015-08-31 | Abbvie Inc | Środki indukujące apoptozę do leczenia raka oraz chorób immunologicznych i autoimmunologicznych |
| AU2010204555B2 (en) * | 2009-01-19 | 2013-03-07 | Abbvie Inc. | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases |
| CN102459236B (zh) * | 2009-05-27 | 2014-10-29 | Abbvie公司 | 激酶活性的嘧啶抑制剂 |
| CA2771984A1 (en) * | 2009-09-20 | 2011-03-24 | Abbott Laboratories | Abt-263 crystalline forms and solvates for use in treating bcl-2 protein related diseases |
| US8840888B2 (en) * | 2009-10-27 | 2014-09-23 | Micromet Ag | Dosage regimen for administering a CD19XCD3 bispecific antibody |
-
2009
- 2009-11-06 RS RS20150306A patent/RS53980B1/sr unknown
- 2009-11-06 DK DK15154416.0T patent/DK2918604T3/en active
- 2009-11-06 PT PT97647101T patent/PT2344539E/pt unknown
- 2009-11-06 DK DK09764710.1T patent/DK2344539T3/en active
- 2009-11-06 HU HUE09764710A patent/HUE025452T2/en unknown
- 2009-11-06 WO PCT/EP2009/007969 patent/WO2010052013A1/en not_active Ceased
- 2009-11-06 PL PL15154416T patent/PL2918604T3/pl unknown
- 2009-11-06 BR BRPI0921341A patent/BRPI0921341A2/pt not_active Application Discontinuation
- 2009-11-06 LT LTEP15154416.0T patent/LT2918604T/lt unknown
- 2009-11-06 CA CA2742242A patent/CA2742242C/en active Active
- 2009-11-06 RS RSP20191232 patent/RS59348B1/sr unknown
- 2009-11-06 ES ES17206868T patent/ES2748126T3/es active Active
- 2009-11-06 PL PL09764710T patent/PL2344539T3/pl unknown
- 2009-11-06 RU RU2011122827/10A patent/RU2536933C2/ru active
- 2009-11-06 AU AU2009313039A patent/AU2009313039B2/en active Active
- 2009-11-06 HU HUE15154416A patent/HUE036922T2/hu unknown
- 2009-11-06 LT LTEP17206868.6T patent/LT3330293T/lt unknown
- 2009-11-06 NO NO15154416A patent/NO2918604T3/no unknown
- 2009-11-06 US US13/127,538 patent/US20110262440A1/en not_active Abandoned
- 2009-11-06 SM SM20180149T patent/SMT201800149T1/it unknown
- 2009-11-06 ES ES15154416.0T patent/ES2662929T3/es active Active
- 2009-11-06 SI SI200931185T patent/SI2344539T1/sl unknown
- 2009-11-06 DK DK17206868.6T patent/DK3330293T3/da active
- 2009-11-06 CN CN200980144400.7A patent/CN102209729B/zh active Active
- 2009-11-06 ES ES09764710.1T patent/ES2535257T3/es active Active
- 2009-11-06 CN CN201610281293.4A patent/CN106390114A/zh active Pending
- 2009-11-06 HU HUE17206868A patent/HUE046222T2/hu unknown
- 2009-11-06 EP EP09764710.1A patent/EP2344539B1/en active Active
- 2009-11-06 SI SI200931817T patent/SI2918604T1/en unknown
- 2009-11-06 RS RS20180309A patent/RS56989B1/sr unknown
- 2009-11-06 KR KR1020117010642A patent/KR101695329B1/ko active Active
- 2009-11-06 PL PL17206868T patent/PL3330293T3/pl unknown
- 2009-11-06 SI SI200931995T patent/SI3330293T1/sl unknown
- 2009-11-06 NZ NZ591312A patent/NZ591312A/xx unknown
- 2009-11-06 MX MX2011002931A patent/MX2011002931A/es active IP Right Grant
- 2009-11-06 JP JP2011533632A patent/JP5798036B2/ja active Active
- 2009-11-06 PT PT151544160T patent/PT2918604T/pt unknown
- 2009-11-06 SM SM20190546T patent/SMT201900546T1/it unknown
- 2009-11-06 SG SG2013076310A patent/SG195549A1/en unknown
- 2009-11-06 EP EP19187179.7A patent/EP3594237A1/en active Pending
- 2009-11-06 EP EP15154416.0A patent/EP2918604B1/en active Active
- 2009-11-06 PT PT172068686T patent/PT3330293T/pt unknown
- 2009-11-06 EP EP17206868.6A patent/EP3330293B1/en active Active
- 2009-11-06 HR HRP20150400TT patent/HRP20150400T1/hr unknown
-
2011
- 2011-05-03 IL IL212651A patent/IL212651A/en active IP Right Grant
-
2014
- 2014-10-13 RU RU2014141180A patent/RU2677324C2/ru active
-
2015
- 2015-03-31 CY CY20151100317T patent/CY1116160T1/el unknown
- 2015-04-27 SM SM201500104T patent/SMT201500104B/xx unknown
- 2015-08-20 JP JP2015163116A patent/JP6130451B2/ja active Active
-
2018
- 2018-03-12 HR HRP20180426TT patent/HRP20180426T1/hr unknown
- 2018-03-14 CY CY20181100310T patent/CY1120022T1/el unknown
- 2018-11-16 HK HK18114719.1A patent/HK1255590B/en unknown
- 2018-12-14 RU RU2018144313A patent/RU2736802C2/ru active
-
2019
- 2019-09-20 HR HRP20191715 patent/HRP20191715T1/hr unknown
- 2019-10-03 CY CY20191101035T patent/CY1122428T1/el unknown
-
2022
- 2022-09-16 US US17/932,739 patent/US20230235053A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012508163A5 (enExample) | ||
| JP2012508164A5 (enExample) | ||
| US20240216431A1 (en) | Methods for expansion or depletion of t-regulatory cells | |
| HRP20191715T1 (hr) | Liječenje dječje akutne limfoblastične leukemije sa bispecifičnim protutijelima protiv cd3xcd19 | |
| HRP20151168T1 (hr) | Lijeäśenje akutne limfoblastiäśne leukemije | |
| Shen et al. | A subset of CXCR5+ CD8+ T cells in the germinal centers from human tonsils and lymph nodes help B cells produce immunoglobulins | |
| Tyor et al. | Cytokine expression in the brain during the acquired immunodeficiency syndrome | |
| Dohgu et al. | Brain pericytes increase the lipopolysaccharide-enhanced transcytosis of HIV-1 free virus across the in vitro blood–brain barrier: evidence for cytokine-mediated pericyte-endothelial cell crosstalk | |
| Fioravanti et al. | Effector CD8+ T cell-derived interleukin-10 enhances acute liver immunopathology | |
| Rajasagi et al. | The role of T cells in herpes stromal keratitis | |
| Krzyzowska et al. | Lactoferrin-functionalized noble metal nanoparticles as new antivirals for HSV-2 infection | |
| US20230084300A1 (en) | Prevention and treatment of infections including those caused by coronavirus | |
| JP2013501814A5 (enExample) | ||
| O’Neil et al. | The role of tissue resident memory CD4 T cells in herpes simplex viral and HIV infection | |
| HRP20171577T1 (hr) | Uporaba t stanica modificiranih himernim receptorom za antigen za liječenje karcinoma | |
| JP2009286793A5 (enExample) | ||
| JP2010132660A5 (enExample) | ||
| Canova et al. | Models of herpes simplex virus latency | |
| JP2004536105A5 (enExample) | ||
| Sarode et al. | Oral lichenoid reaction: A review | |
| McTavish et al. | Immune characteristics correlating with HSV‐1 immune control and effect of squaric acid dibutyl ester on immune characteristics of subjects with frequent herpes labialis episodes | |
| CN109563156A (zh) | 抗体和抗病毒剂的抗hsv协同活性 | |
| Samah et al. | Nerve growth factor stimulation promotes CXCL-12 attraction of monocytes but decreases human immunodeficiency virus replication in attracted population | |
| Vey et al. | A phase I study of the anti-natural killer inhibitory receptor (KIR) monoclonal antibody (1-7F9, IPH2101) in elderly patients with acute myeloid leukemia (AML): clinical and immunological effects of a single dose followed by repeated dosing. | |
| O’neil et al. | The Role of Tissue Resident Memory CD4 T Cells in Herpes Simplex Viral and HIV Infection. Viruses 2021, 13, 359 |